Clinical Trials

A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Hematological Malignancies

This clinical trial a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of the novel drug, VLS-101. The trial is assessing VLS-101 monotherapy across a range of dose levels when administered to patients with previously treated hematologic cancers. More details are available at ClinicalTrials.gov or by contacting us.

A Phase 2 Study of VLS-101 in Patients with Solid Tumors

This clinical trial is a Phase 2 study evaluating the efficacy, safety, pharmacokinetics, immunogenicity, and pharmacodynamics of VLS-101 in patients with metastatic solid tumors. Accrual of subjects with any of the following tumor types is planned: previously treated triple-negative breast cancer; previously treated hormone receptor-positive and/or HER2-positive breast cancer; and previously treated non-squamous, non-small-cell lung cancer. More details are available at ClinicalTrials.gov or by contacting us.

Now Leaving The VelosBio Site.

Disclaimer Close Button SVG

Disclaimer: The information you have requested is not provided by VelosBio Inc. (“VelosBio”) but by a third party and should not be construed as representing the views of VelosBio. VelosBio does not guarantee the accuracy or completeness of this information and is not liable for any delays, inaccuracies, errors in, or omissions of any such information, or for any actions taken in reliance on this information, or for any damages arising therefrom.

Continue Offsite